Toxic Epidermal Necrolysis in a Boy with Dravet Syndrome: Clinical Case
Aset Kh. Ibisheva,
Lechi R. Kagaev,
Linda V.-M. Dzhabrailova,
Malika M. Gadueva,
Iman Sh. Masayeva,
Madina A. Denilkhanova https://doi.org/10.15690/pf.v22i1.2857
Abstract
Background. Toxic epidermal necrolysis (TEN) is significant public health issue as it is associated with high mortality.
Clinical case description. The authors have described the case of TEN in a boy with Dravet syndrome. Data on TEN course and real prevalence in children around the world is limited due to its rare incidence.
Conclusion. Successful experience in TEN management has been presented.
Supporting agencies: Not specified.
About the Authors
Aset Kh. Ibisheva
Republican Children’s Clinical Hospital named after E.P. Glinka
Russian Federation
Disclosure of interest:
Russian Federation
101, Bisultanova Str., Grozny, 364028
телефон: +7 (928) 129-16-13
Disclosure of interest:
Not declared.
Lechi R. Kagaev
Republican Children’s Clinical Hospital named after E.P. Glinka
Russian Federation
Disclosure of interest:
Russian Federation
Grozny
Disclosure of interest:
Not declared.
Linda V.-M. Dzhabrailova
Republican Children’s Clinical Hospital named after E.P. Glinka
Russian Federation
Disclosure of interest:
Russian Federation
Grozny
Disclosure of interest:
Not declared.
Malika M. Gadueva
Republican Children’s Clinical Hospital named after E.P. Glinka
Russian Federation
Disclosure of interest:
Russian Federation
Grozny
Disclosure of interest:
Not declared.
Iman Sh. Masayeva
Republican Children’s Clinical Hospital named after E.P. Glinka
Russian Federation
Disclosure of interest:
Russian Federation
Grozny
Disclosure of interest:
Not declared.
Madina A. Denilkhanova
Republican Children’s Clinical Hospital named after E.P. Glinka
Russian Federation
Disclosure of interest:
Russian Federation
Grozny
Disclosure of interest:
Not declared.
References
1. Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021;57(9):895. doi: https://doi.org/10.3390/medicina57090895
2. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39. doi: https://doi.org/10.1186/1750-1172-5-39
3. Abulatan IT, Ben-David SG, Morales-Colon LA, et al. A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Cureus. 2023;15(11):e48728. doi: https://doi.org/10.7759/cureus.48728
4. Enescu CD, Elder AJ, Deirawan H, Moossavi M. To Debride or Not to Debride: A Review of Wound Management for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Cureus. 2024;16(3):e55350. doi: https://doi.org/10.7759/cureus.55350
5. Acar A, Yoldas AH, Turk BG, et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: 11-year Demographic Clinical and Prognostic Characteristics. Indian J Dermatol. 2022;67(1):12–18. doi: https://doi.org/10.4103/ijd.IJD_671_21
6. Lobão B, Martins C, Sousa M, et al. Phenytoin-induced Lyell’s syndrome. BMJ Case Rep. 2012;2012:bcr2012007746. doi: https://doi.org/10.1136/bcr-2012-007746
7. Antoon JW, Goldman JL, Shah SS, Lee B. A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. J Allergy Clin Immunol Pract. 2019;7(1):244–250.e1. doi: https://doi.org/10.1016/j.jaip.2018.05.024
8. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005;64(7):1134–1138. doi: https://doi.org/10.1212/01.WNL.0000156354.20227.F0
9. Abtahi-Naeini B, Dehghan MS, Paknazar F, et al. Clinical and Epidemiological Features of Patients with Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Iran: Different Points of Children from Adults. Int J Pediatr. 2022;2022:8163588. doi: https://doi.org/10.1155/2022/8163588
10. Talebi R MD, Saki N MD, Raeisi Shahraki H PhD, Owji SH MD. An Epidemiological Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis during 2010-2015 at Shahid Faghihi Hospital, Shiraz, Iran. Iran J Med Sci. 2018;43(4):421–425.
11. Liotti L, Caimmi S, Bottau P, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3- S):52–60. doi: https://doi.org/10.23750/abm.v90i3-S.8165
12. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144–148. doi: https://doi.org/10.2340/00015555-0214
13. Zhang J, Lei Z, Xu C, et al. Current Perspectives on Severe Drug Eruption. Clin Rev Allergy Immunol. 2021;61(3):282–298. doi: https://doi.org/10.1007/s12016-021-08859-0
14. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33–36. doi: https://doi.org/10.1001/archderm.139.1.33
15. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1991;282(5388):490–493. doi: https://doi.org/10.1126/science.282.5388.490
16. Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005;116(4):923–924. doi: https://doi.org/10.1016/j.jaci.2005.06.029
17. Arévalo JM, Lorente JA, González-Herrada C, Jiménez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma. 2000;48(3):473–478. doi: https://doi.org/10.1097/00005373-200003000-00017
18. Liotti L, Caimmi S, Bottau P, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3- S):52–60. doi: https://doi.org/10.23750/abm.v90i3-S.8165
19. González-Herrada C, Rodríguez-Martín S, Cachafeiro L, et al. Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J Invest Dermatol. 2017;137(10):2092–2100. doi: https://doi.org/10.1016/j.jid.2017.05.022
20. Narita YM, Hirahara K, Mizukawa Y, et al. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol. 2011;38(3):236–245. doi: https://doi.org/10.1111/j.1346-8138.2010.01154.x
Review
For citations:
Ibisheva A.Kh., Kagaev L.R., Dzhabrailova L.V., Gadueva M.M., Masayeva I.Sh., Denilkhanova M.A. Toxic Epidermal Necrolysis in a Boy with Dravet Syndrome: Clinical Case. Pediatric pharmacology. 2025;22(1):12-18. (In Russ.) https://doi.org/10.15690/pf.v22i1.2857
Views:
309
Email this article 